Ethylene Glycols

An ethylene compound with two hydroxy groups (-OH) located on adjacent carbons. They are viscous and colorless liquids. Some are used as anesthetics or hypnotics. However, the class is best known for their use as a coolant or antifreeze.
DrugDrug NameDrug Indication
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB00059PegaspargaseFor treatment of acute lymphoblastic leukemia
DB01495DichloralphenazoneNot Available
DB01563Chloral hydrateMainly used as a hypnotic in the treatment of insomnia; however, it is only effective as a hypnotic for short-term use. May be used as a routine sedative preoperatively to decrease anxiety and cause sedation and/or sleep with respiration depression or cough reflex.
DB04682Octylphenoxy polyethoxyethanolNot Available
DB04978SP1049CIntended for the treatment of carcinoma of the oesophagus.
DB05321PEG-uricaseInvestigated for use/treatment in hyperuricemia.
DB05446LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
DB05718Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB06439TyloxapolTyloxapol is an inhaled surfactant that assists in removing and liquefying and removing bronchopulmonary secretions with mucus and pus. Tyloxapol is administered either through nebulized solution or a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.
DB06611PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DB06804Nonoxynol-9Nonoxynol 9 is a surfactant spermicide used for contraception in spermicidal creams, jellies, foams, gel, and lubricants. It is also used in conjuction with other methods of contraception, including condoms, cervical caps and diaphragms.
DB06811PolidocanolPolidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
DB08894PeginesatidePeginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis
DB08904Certolizumab pegolCertolizumab pegol has been approved for several different conditions listed below: - Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy. - Treatment of adult patients with moderate to severely active rheumatoid arthritis. - Treatment of adult patients with active psoriatic arthritis. - Treatment of adult patients with active ankylosing spondylitis. - Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.[FDA label] - Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.[L5819] In Canada, certolizumab pegol is additionally approved in combination with [methotrexate] for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.[L5825] Inflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.[L5840] TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.[A176660]
DB09049NaloxegolIndicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
DB09107Methoxy polyethylene glycol-epoetin betaFor the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
DB09122Peginterferon beta-1aFor the treatment of patients with relapsing forms of multiple sclerosis.
DB09208PegloticaseFor the treatment of chronic gout in adult patients refractory to conventional therapy.
DB09287Polyethylene glycolUsed to treat and prevent constipation.
DB11063Polysorbate 80It is used as a solubilizer, antimicrobial preservative and disinfectant [L1853].
DB11077Polyethylene glycol 400PEG-400 has been indicated for the temporary relief of burning and irritation due to dryness of the eye, and for protection against further irritation and desiccation [L1795], [L1796], [L1797].
DB11161Polyethylene glycol 300Indicated as a lubricant in over-the-counter ophthalmic solutions to temporarily relieve redness, burning and irritation of the eyes.
DB11178Polysorbate 20Not Available
DB11252Poloxamer 407Not Available
DB11333Poloxamer 188Indicated to reduce viscosity in the blood before transfusions.
DB11451PoloxaleneNot Available
DB11567Insulin peglisproNot Available
DB11635TocofersolanTocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age [L2371].
DB12842PegamotecanNot Available
DB13933Nonacog beta pegolNonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56]
DB09329Antihemophilic Factor (Recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064]. This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].
DB02078TriglymeNot Available
DB02327Triethylene glycolNot Available
DB02650TrichloroacetaldehydeNot Available
DB14730Calaspargase pegolThis drug is is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years [FDA label]. The pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL [L4890]. The FDA approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL when administering calaspargase, 2500 U/m2 intravenously, at 3-week intervals.
DB06592PegargiminaseInvestigated for use/treatment in melanoma and hepatocellular carcinoma.
DB14767Peginterferon lambda-1aNot Available
DB14951Etirinotecan pegolNot Available
DB14953Firtecan pegolNot Available
DB15112Somatropin pegolNot Available
DB15441Lulizumab pegolNot Available
DrugDrug NameTargetType
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2C9enzyme
DB00059PegaspargaseL-asparaginetarget
DB00059PegaspargaseThyroxine-binding globulincarrier
DB04682Octylphenoxy polyethoxyethanolTroponin C, skeletal muscletarget
DB04978SP1049CDNA topoisomerase 2-alphatarget
DB05321PEG-uricaseUric acid degradation bifunctional proteintarget
DB05446LJP 1082Beta-2-glycoprotein 1target
DB06439TyloxapolLipoprotein lipasetarget
DB06804Nonoxynol-9Prostaglandin G/H synthase 2enzyme
DB08894PeginesatideErythropoietin receptortarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB08904Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DB09049NaloxegolCytochrome P450 3A4enzyme
DB09049NaloxegolCytochrome P450 2D6enzyme
DB09049NaloxegolCytochrome P450 2C19enzyme
DB09049NaloxegolMu-type opioid receptortarget
DB09107Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
DB09208PegloticaseUric acidtarget
DB11077Polyethylene glycol 400Oxidoreductase HTATIP2target
DB11077Polyethylene glycol 400Cytochrome P450 4A11enzyme
DB11077Polyethylene glycol 400Alcohol dehydrogenase class-3enzyme
DB11077Polyethylene glycol 400Sulfotransferase 1A1enzyme
DB11077Polyethylene glycol 400Ectonucleotide pyrophosphatase/phosphodiesterase family member 1target
DB11635TocofersolanMultidrug resistance protein 1target
DB11635TocofersolanLeukotriene-B(4) omega-hydroxylase 1enzyme
DB11635TocofersolanAlpha-tocopherol transfer proteintransporter
DB11635TocofersolanScavenger receptor class B member 1transporter
DB11635TocofersolanNiemann-Pick C1-like protein 1transporter
DB11635TocofersolanATP-binding cassette sub-family G member 5transporter
DB11635TocofersolanATP-binding cassette sub-family G member 8transporter
DB11635TocofersolanATP-binding cassette sub-family A member 1transporter
DB11635TocofersolanSEC14-like protein 4transporter
DB11635TocofersolanSEC14-like protein 2transporter
DB11635TocofersolanSEC14-like protein 3transporter
DB11635TocofersolanApolipoprotein B receptortransporter
DB11635TocofersolanCytochrome P450 3A4enzyme
DB13933Nonacog beta pegolCoagulation factor VIItarget
DB13933Nonacog beta pegolCoagulation factor VIIItarget
DB13933Nonacog beta pegolCoagulation factor Xtarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factortarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factorcarrier
DB02078TriglymeOuter-membrane lipoprotein LolBtarget
DB02078TriglymeProfilin-2target
DB02078TriglymeOuter-membrane lipoprotein LolBtarget
DB02078TriglymeUncharacterized proteintarget
DB02078TriglymeSerine acetyltransferasetarget
DB02078TriglymeTyrosine-protein kinase Fyntarget
DB02078TriglymePeptidyl-prolyl cis-trans isomerase F, mitochondrialtarget
DB02078TriglymeTranscriptional regulator, GntR familytarget
DB02078TriglymeABC transporter, periplasmic substrate-binding proteintarget
DB02078TriglymeTransketolasetarget
DB02327Triethylene glycolAcetolactate synthase, catabolictarget
DB02327Triethylene glycolArabinogalactan endo-1,4-beta-galactosidasetarget
DB02327Triethylene glycolPhosphoserine aminotransferasetarget
DB14730Calaspargase pegolL-asparaginetarget